Guggenheim initiated coverage of 10x Genomics with a Buy rating and $60 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TXG:
- 10x Genomics just upgraded at BofA, here’s why
- 10x Genomics collaborates with NIH CARD on neuroscience research
- Curio Bioscience to ‘vigorously defend’ against 10x Genomics’ allegations
- NanoString downgraded to Neutral from Overweight at JPMorgan
- NanoString downgraded to Neutral from Outperform at Baird